53 related articles for article (PubMed ID: 25422161)
1. Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E.
Zismanov V; Attar-Schneider O; Lishner M; Heffez Aizenfeld R; Tartakover Matalon S; Drucker L
Int J Oncol; 2015 Feb; 46(2):860-70. PubMed ID: 25422161
[TBL] [Abstract][Full Text] [Related]
2. Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth.
Wang M; Wu D; Liu P; Deng J
Exp Hematol Oncol; 2014; 3(1):27. PubMed ID: 25422792
[TBL] [Abstract][Full Text] [Related]
3. Dilemmas in treating smoldering multiple myeloma.
Ahn IE; Mailankody S; Korde N; Landgren O
J Clin Oncol; 2015 Jan; 33(1):115-23. PubMed ID: 25422486
[TBL] [Abstract][Full Text] [Related]
4. Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.
Yokokura S; Yurimoto S; Matsuoka A; Imataki O; Dobashi H; Bandoh S; Matsunaga T
BMC Cancer; 2014 Nov; 14():882. PubMed ID: 25424011
[TBL] [Abstract][Full Text] [Related]
5. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S; Culjkovic-Kraljacic B; Bergeron J; Caplan S; Cocolakis E; Lambert C; Lau CJ; Zahreddine HA; Miller WH; Borden KL
Haematologica; 2015 Jan; 100(1):e7-9. PubMed ID: 25425688
[No Abstract] [Full Text] [Related]
7. A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Zhu J; Wang M; Yu Y; Qi H; Han K; Tang J; Zhang Z; Zeng Y; Cao B; Qiao C; Zhang H; Hou T; Mao X
Oncotarget; 2015 Jan; 6(1):185-95. PubMed ID: 25474140
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells.
Ghurye RR; Stewart HJ; Chevassut TJ
Cytokine; 2015 Feb; 71(2):415-7. PubMed ID: 25482841
[No Abstract] [Full Text] [Related]
9. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.
Muz B; de la Puente P; Azab F; Luderer M; Azab AK
Blood Cancer J; 2014 Dec; 4(12):e262. PubMed ID: 25479569
[No Abstract] [Full Text] [Related]
10. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
Andreu-Vieyra CV; Berenson JR
Ther Adv Hematol; 2014 Dec; 5(6):197-210. PubMed ID: 25469210
[TBL] [Abstract][Full Text] [Related]
11. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
[TBL] [Abstract][Full Text] [Related]
12. The osteoblastic niche in the context of multiple myeloma.
Toscani D; Bolzoni M; Accardi F; Aversa F; Giuliani N
Ann N Y Acad Sci; 2015 Jan; 1335():45-62. PubMed ID: 25424768
[TBL] [Abstract][Full Text] [Related]
13. eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling.
Attar-Schneider O; Pasmanik-Chor M; Tartakover-Matalon S; Drucker L; Lishner M
Oncotarget; 2015 Feb; 6(6):4315-29. PubMed ID: 25717031
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.
Beider K; Bitner H; Leiba M; Gutwein O; Koren-Michowitz M; Ostrovsky O; Abraham M; Wald H; Galun E; Peled A; Nagler A
Oncotarget; 2014 Nov; 5(22):11283-96. PubMed ID: 25526031
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
[TBL] [Abstract][Full Text] [Related]
16. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
Weinhold N; Meissner T; Johnson DC; Seckinger A; Moreaux J; Försti A; Chen B; Nickel J; Chubb D; Rawstron AC; Doughty C; Dahir NB; Begum DB; Young K; Walker BA; Hoffmann P; Nöthen MM; Davies FE; Klein B; Goldschmidt H; Morgan GJ; Houlston RS; Hose D; Hemminki K
Haematologica; 2015 Mar; 100(3):e110-3. PubMed ID: 25480495
[No Abstract] [Full Text] [Related]
17. Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
Clemens J; Seckinger A; Hose D; Theile D; Longo M; Haefeli WE; Burhenne J; Weiss J
Cancer Chemother Pharmacol; 2015 Feb; 75(2):281-91. PubMed ID: 25477008
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
An G; Acharya C; Deng S; Yi S; Xu Y; Qin X; Sui W; Li Z; Shi L; Zang M; Feng X; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Tai YT; Qiu L
Exp Hematol; 2015 Mar; 43(3):168-176.e2. PubMed ID: 25462022
[TBL] [Abstract][Full Text] [Related]
19. Role of toll-like receptors in multiple myeloma and recent advances.
Thakur KK; Bolshette NB; Trandafir C; Jamdade VS; Istrate A; Gogoi R; Cucuianu A
Exp Hematol; 2015 Mar; 43(3):158-67. PubMed ID: 25462020
[TBL] [Abstract][Full Text] [Related]
20. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.
Wang Y; Muylaert C; Wyns A; Vlummens P; De Veirman K; Vanderkerken K; Zaal E; Berkers C; Moreaux J; De Bruyne E; Menu E
Haematologica; 2024 Jan; 109(1):256-271. PubMed ID: 37470139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
